Pharmacokinetics and Bioequivalence Evaluation of Two Rosuvastatin Calcium 20 mg Tablets: A Single Oral Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Volunteers under Fasting Conditions
Objectives: To compare the rate and extent of absorption of Racor® 20 mg (Rosuvastatin calcium 20 mg) tablet of Laboratorios Leti, S.A.V., with Crestor® 20 mg (Rosuvastatin calcium 20 mg) tablet of AstraZeneca, UK Limited in healthy adult human subjects under fasting conditions. Method: This was an open label, analyst blind, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, crossover, bioequivalence study in healthy, adult, human subjects under fasting condition. Twenty-four (24) subjects were planned as per the protocol and all subjects completed both periods of the study. The concentrations of Rosuvastatin in plasma were quantitated using a validated LC-MS/MS method of analysis and plasma levels were submitted for statistical analysis. Cmax, AUC0-t, AUC0-∞, Tmax, t1/2, Kel (hrs-1), percent AUC extrapolated [100 * (AUC0-∞ - AUC0-t)/AUC0-∞] (AUC_%Extrapobs) were calculated for rosuvastatin in plasma using SAS® version 9.1.3, SAS Institute. Inc. USA.CARY. ANOVA, 90% confidence interval using Schuirmann’s two one-sided test for bioequivalence, power and ratio analysis, for lntransformed pharmacokinetic parameters Cmax, AUC0-t and AUC0-∞ were computed and reported for Rosuvastatin in plasma for BE. Results: Data showed that 90% confidence intervals for the test/reference geometric mean ratios (GMR) of Cmax (95.01 - 112.66), AUC0-t (93.38 - 111.67) and AUC0-∞ (93.65 - 111.29) were within the BE (80% - 125%) acceptance range. Conclusions: Two products formulation, reference (R) Crestor® (rosuvastatin calcium) of AstraZeneca and test (T), Racor® (rosuvastatin calcium) of Laboratorios Leti S.A.V., with a single dose of 20 mg, under fasting conditions were bioequivalent. No severe, serious or unexpected adverse events (AEs) were reported in this study.
References
[1]
Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. (2019) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. European Heart Journal, 41, 111-188. https://doi.org/10.1093/eurheartj/ehz455
[2]
Townsend, N., Nichols, M., Scarborough, P. and Rayner, M. (2015) Cardiovascular Disease in Europe—Epidemiological Update 2015. European Heart Journal, 36, 2696-2705. https://doi.org/10.1093/eurheartj/ehv428
[3]
Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., Macfarlane, P.W., et al. (1995) Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. New England Journal of Medicine, 333, 1301-1308. https://doi.org/10.1056/nejm199511163332001
[4]
Scandinavian Simvastatin Survival Study Group (1994) Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet, 344, 1383-1389. https://doi.org/10.1016/s0140-6736(94)90566-5
[5]
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G. and Pyarala, K. (1998) Prevention of Coronary Heart Disease in Clinical Practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis, 140, 199-270. https://doi.org/10.1016/s0021-9150(98)90209-x
[6]
Lipsy R. (2003) The National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of Managed Care & Specialty Pharmacy, 9, 2-5.
[7]
McKenney, J.M. (1998) The Cost of Treating Dyslipidaemia Using National Cholesterol Education Program (NCEP) Guidelines. PharmacoEconomics, 14, 19-28. https://doi.org/10.2165/00019053-199814003-00003
[8]
Luvai, A., Mbagaya, W., Hall, A.S. and Barth, J.H. (2012) Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease. Clinical Medicine Insights: Cardiology, 6, 17-33. https://doi.org/10.4137/cmc.s4324
[9]
White, C.M. (2002) A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. Journal of Clinical Pharmacology, 42, 963-970. https://doi.org/10.1177/009127002401102876
McTaggart, F. (2003) Comparative Pharmacology of Rosuvastatin. Atherosclerosis Supplements, 4, 9-14. https://doi.org/10.1016/s1567-5688(03)00004-7
[12]
United States Food and, Drug Administration. Crestor (Rosuvastatin Calcium) Tablets. Prescribing Information Label. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021366s026lbl.pdf
[13]
Istvan, E.S. and Deisenhofer, J. (2001) Structural Mechanism for Statin Inhibition of HMG-CoA Reductase. Science, 292, 1160-1164. https://doi.org/10.1126/science.1059344
[14]
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., et al. (2001) Preclini-cal and Clinical Pharmacology of Rosuvastatin, a New 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor. The American Journal of Cardiology, 87, 28-32. https://doi.org/10.1016/s0002-9149(01)01454-0
[15]
Warwick, M.J., Dane, A.L., Raza, A. and Schneck, D.W. (2000) Single- and Multiple-Dose Pharmacokinetics and Safety of the New HMG-CoA Reductase Inhibitor ZD4522. Atherosclerosis, 151, 39. https://doi.org/10.1016/s0021-9150(00)80175-6
[16]
Martin, P.D., Mitchell, P.D. and Schneck, D.W. (2002) Pharmacodynamic Effects and Pharmacokinetics of a New HMG‐CoA Reductase Inhibitor, Rosuvastatin, after Morning or Evening Administration in Healthy Volunteers. British Journal of Clinical Pharmacology, 54, 472-477. https://doi.org/10.1046/j.1365-2125.2002.01688.x
[17]
Calza, L. (2009) Long-Term Use of Rosuvastatin: A Critical Risk Benefit Appraisal and Comparison with Other Antihyperlipidemics. Drug, Healthcare and Patient Safety, 1, 25-33. https://doi.org/10.2147/dhps.s4928
[18]
Shah, Y., Iqbal, Z., Ahmad, L., Nazir, S., Watson, D.G., Khuda, F., et al. (2015) Determination of Rosuvastatin and Its Metabolite N-Desmethyl Rosuvastatin in Human Plasma by Liquid Chromatography-High Resolution Mass Spectrometry: Method Development, Validation, and Application to Pharmacokinetic Study. Journal of Liquid Chromatography & Related Technologies, 38, 863-873. https://doi.org/10.1080/10826076.2014.982866
[19]
Simonson, S.G., Martin, P.D., Mitchell, P., Schneck, D.W., Lasseter, K.C. and Warwick, M.J. (2003) Pharmacokinetics and Pharmacodynamics of Rosuvastatin in Subjects with Hepatic Impairment. European Journal of Clinical Pharmacology, 58, 669-675. https://doi.org/10.1007/s00228-002-0541-7
[20]
Martin, P.D., Kemp, J., Dane, A.L., Warwick, M.J. and Schneck, D.W. (2002) No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers. The Journal of Clinical Pharmacology, 42, 1352-1357. https://doi.org/10.1177/0091270002042012008
[21]
World Medical Association (2013) World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA, 310, 2191-2194. https://doi.org/10.1001/jama.2013.281053
[22]
ICH (1996) Harmonised Tripartite Guideline for Good Clinical Practice (E6). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH/GCP. https://www.ema.europa.eu/en/homepage
[23]
Kanukula, R., Salam, A., Rodgers, A. and Kamel, B. (2021) Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clinical Pharmacokinetics, 60, 165-175. https://doi.org/10.1007/s40262-020-00978-9
[24]
Morais, J.A.G. and do Rosário Lobato, M. (2010) The New European Medicines Agency Guideline on the Investigation of Bioequivalence. Basic & Clinical Pharmacology & Toxicology, 106, 221-225. https://doi.org/10.1111/j.1742-7843.2009.00518.x
[25]
CHMP (2014) Committee for Medicinal Products for Human Use. Assessment Report. https://www.ema.europa.eu/en/homepage
[26]
CHMP (2010) Guideline on the Investigation of Bioequivalence. https://www.ema.europa.eu/en/homepage
[27]
Scott, M., et al. (2019) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139, e1082-e1143. https://doi.org/10.1161/CIR.0000000000000698
[28]
Martin, P.D., Dane, A.L., Nwose, O.M., Schneck, D.W. and Warwick, M.J. (2002) No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor. Journal of Clinical Pharmacology, 42, 1116-1121. https://doi.org/10.1177/009127002401382722
[29]
Andrade, C. (2015) Bioequivalence of Generic Drugs. The Journal of Clinical Psychiatry, 76, e1130-e1131. https://doi.org/10.4088/jcp.15f10300
[30]
Pena, E., Inatti, A. and Martín, X.S. (2023) Bioequivalence Study of Two Formulations of Rivaroxaban in Healthy Adult Subjects under Fasting Conditions. American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2, Article 8. https://doi.org/10.25259/ajpps_2023_008
[31]
Pena, E., Inatti, A., Taly, A., Chacón, J.G. and Serrano-Martin, X. (2023) Bioequivalence Assessment of Two Formulations of Empagliflozin in Healthy Adult Subjects. American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2, Article 19. https://doi.org/10.25259/ajpps_2023_019
[32]
Pena, E., Inatti, A. and Martin, X.S. (2023) Bioequivalence Study of Diclofenac 150 Mg XR: A Single-Dose, Randomized, Open Label, 2-Period Crossover Study in Healthy Adult Volunteers. Journal of Biosciences and Medicines, 11, 23-32. https://doi.org/10.4236/jbm.2023.1111003
[33]
Pena, E., Inatti, A., Taly, A. and Serrano, X. (2024) Relative Bioavailability Study of Ticagrelor in Healthy Subjects under Fasting Conditions. American Journal of Pharmacotherapy and Pharmaceutical Sciences, 3, Article 8. https://doi.org/10.25259/ajpps_2024_008
